Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01806324 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Pharmacokinetics and Potential Drug Interactions of a Fixed-dose Combination Tablet, HL-040XC, in Healthy Male Subjects
A Phase 1 study, sponsored by HanAll BioPharma Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01806324: Completed Phase 1 study, sponsored by HanAll BioPharma Co..
NCT01806324 is a Phase 1 study that has completed, run by HanAll BioPharma Co.. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01806324, a Phase 1 study, has completed, sponsored by HanAll BioPharma Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The objective of this study is: To evaluate the pharmacokinetics and safety of an experimental combination tablet containing 20 mg atorvastatin and 50 mg losartan potassium when administered orally as a single dose to healthy male subjects, compared with the concomitant administration of 20 mg atorvastatin and 50 mg losartan potassium tablets.
Primary Outcome
To evaluate its bioequivalency in Cmax and AUC of each test group
Interventions
- DRUG HL040XC
- DRUG Losartan + Atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-04 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
What the finished NCT01806324 record still lists
NCT01806324 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 2 interventions - of which HL040XC is the first listed.
NCT01806324 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01806324 about?
NCT01806324 is a clinical study titled "A Study to Evaluate Pharmacokinetics and Potential Drug Interactions of a Fixed-dose Combination Tablet, HL-040XC, in Healthy Male Subjects". The objective of this study is: To evaluate the pharmacokinetics and safety of an experimental combination tablet containing 20 mg atorvastatin and 50 mg losartan potassium when administered orally as a single dose to healthy male subjects, compared with the concomitant administration of 20 mg ator...
What is the current status of trial NCT01806324?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2012-04. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01806324?
The interventions under investigation include: HL040XC (DRUG), Losartan + Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT01806324?
This trial is sponsored by HanAll BioPharma Co., which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01806324's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia